
Doty Ojwach
Post-Doctoral Fellow
-
Occupation:Post-Doctoral Fellow
-
Email:
-
EDUCATION:PhD
EXPERIENCE
Dr Doty Ojwach earned her Doctorate in Virology from the University of KwaZulu-Natal at the HIV Pathogenesis program. In her current role at RIRCA, Doty leverages her profound scientific knowledge and a deep understanding of the intricate relationship between HIV replication and HIV immunity. Her primary focus is on investigating the consequences of maternal HIV and/or CMV co-infection and how these dynamics impact the development of fetal immunity, starting by investigations in the placenta. Doty’s work represents a vital contribution to our understanding of the complex interactions between viral infections and the immune system during pregnancy.
AWARDS
Award Name | Dates | Presentation Title | Amount |
New Investigator award-Conferences on retroviruses and opportunistic infections | 9-13 March 2025 | First-line Regimen Antiretroviral drugs disrupt placental macrophage function and vascular development, which can be rescued by exogenous FXIIIA1-Poster | $3000 |
The Loke Centre for Trophoblast Research – Cambridge University | 9-13 September 2024 | First-line Regimen Antiretroviral drugs disrupt placental macrophage function and vascular development, which can be rescued by exogenous FXIIIA1 | £150 |
3rd Lindau Nobel online sciathon team project-winner | 28-30 April 2023 | Phototherapy for the Treatment of Endometriosis (video recording) | |
Female Science Talents-award | 01/01/2023 – 31/01/2023 | 1-year mentorship, 2-times career training in Germany, and oral presentation opportunity at Berlin Falling Walls 2023 | £8000 |
72nd Lindau Nobel Laureate Meeting | 25-30 June 2023 | Phototherapy for the Treatment of Endometriosis (Oral and video recording) |
AWARDED GRANTS
Funding Body/Grant Name | Dates | Project Title | Amount |
UK-SAMRC: RFA-GIPD-03-2024 | Jan 2025 – Dec 2028 | The impact of antiretroviral drugs on placental vascular development and macrophage function. | ZAR 9m |
AREF-312-OJWA-S-C102-Seed grant | 06/01/2025 – 31/01/2026 | Exploring Macrophage Function in Maternal HIV and Antiretroviral Drugs on Placental Vascular Development | £50000 |
RP10094-SAMRC-SIR | 01/01/2023 – 31/12/2025 | Mechanisms by which maternal HIV, CMV infection and antiretroviral therapy lead to adverse birth outcomes | £25000 |
PSTD2204285217-NRF | 01/01/2023 – 31/12/2024 | Mechanisms by which maternal HIV, HCMV infection and antiretroviral therapy impacts on the placenta leading to adverse birth outcomes | £21000 |
COB- Travelling Fellowship JCSTF23081194 | 01/02/2024 – 29/03/2024 | Investigating Macrophage Characteristics in Pre-term and Term Placentae during Maternal HIV Infection and Antiretroviral Therapy Treatment | £3000 |
Africa Oxford Initiative (AFOX)- Travelling Fellowship | 01/02/2024 – 29/03/2024 | Investigating Macrophage Characteristics in Pre-term and Term Placentae during Maternal HIV Infection and Antiretroviral Therapy Treatment | £5000 |
AREF- 325-OJWA-F-C0914-research development (RDF) | 01/10/2022 – 31/10/2023 | Characterizing macrophages in term placentae exposed to maternal HIV and human cytomegalovirus co-infection (2022-2023) | £39000 |